ASE · Biotechnology

MTNB (MTNB) Stock

$0.33 +37.53% ASE: MTNB Healthcare

Valuation

MetricValue
Price$0.33
Market Cap$2.13M
P/E Ratio-0.32
P/B Ratio0.83
P/S Ratio0.00
EPS (TTM)$-2.00
52-Week High$3.09
52-Week Low$0.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-200.00%
ROA-142.86%
ROCE-140.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.39
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$3.0M$1.0M$0$0
Operating Profit$-25.0M$-25.0M$-24.0M$-25.0M$-7.0M
Net Profit$-23.0M$-21.0M$-23.0M$-24.0M$-10.0M
EPS$-5.04$-3.00$-5.28$-4.98$-2.00
Op Margin-74954.6%-771.3%-2168.4%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$61.0M$79.0M$25.0M$13.0M$7.0M
Total Liabilities$9.0M$42.0M$6.0M$5.0M$2.0M
Cash$21.0M$7.0M$5.0M$7.0M$4.0M
Borrowings$5.0M$4.0M$4.0M$3.0M$1.0M

Latest News

Top Premarket Decliners MT Newswires · Jul 14, 2026 GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma Business Wire · Jul 13, 2026 Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals GlobeNewswire · Jul 13, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance GlobeNewswire · Jun 26, 2026 Matinas BioPharma Files $150 Million Mixed Shelf Registration MT Newswires · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-19.0M$-15.0M$-16.0M$-7.0M
Investing Cash Flow$17.0M$4.0M$13.0M$9.0M$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$9.0M$-14.0M$-2.0M$2.0M$-3.0M
Free Cash Flow$-15.0M$-20.0M$-15.0M$-16.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-222.30%
Quick Ratio1.32
Interest Coverage—
Return 1Y-65.59%
Return 3Y-98.13%
Return 5Y-99.05%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
ADIL $3.33 +1.22% -1.14 $3.20M 0.00%
ADXNAddex Therapeutics Ltd $5.89 -0.17% -0.72 $4.24M 0.00%
BCLIBrainstorm Cell Therapeutics Inc. $0.98 +6.52% -1.04 $10.81M 0.00%
CDIO $1.62 +4.52% -0.53 $3.35M 0.00%

About MTNB

MTNB is led by CEO Jerome D. Jabbour, employs 3 people, headquartered in US, publicly traded since 2014.

MTNB stock trades at $0.33 with a market capitalization of $2.13M. The stock is valued at a price-to-earnings (P/E) ratio of -0.32, price-to-book of 0.83, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.23 and $3.09, and currently trades 89.3% below its 52-week high.

On profitability, MTNB generates a return on equity (ROE) of -200.00%, return on capital employed of -140.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides